To learn more about FoundationOne Heme, our comprehensive genomic profiling test designed specifically for patients with hematologic malignancies, please visit our website. FoundationOne Heme is validated to detect the four main classes of genomic alterations in more than 400-cancer related genes as well as known, novel, and complex fusions.
If you are interested in connecting with one of our biopharma professionals to discuss partnership opportunities, please contact email@example.com. You can also learn more about our biopharma partnerships by visiting our website.
Sign up for email updates from Foundation Medicine below, including the option to download a case study describing how we can help with clinical trial enrollment.